Table 15.13
Immunosuppression Use for Maintenance by Regimen
Two Years Following Transplantation, 1998 to 2005
Recipients with Heart Transplants

|  | Transplant Year |       |       |       |       |       |       |       |
|--|-----------------|-------|-------|-------|-------|-------|-------|-------|
|  | 1998            | 1999  | 2000  | 2001  | 2002  | 2003  | 2004  | 2005  |
| Transplants                            | 2,348           | 2,188 | 2,199 | 2,202 | 2,155 | 2,057 | 2,015 | 2,125 |
| Functioning Graft at 2 Years<br>PostTx | 1,826           | 1,669 | 1,729 | 1,747 | 1,715 | 1,655 | 1,645 | 1,710 |
| With Maintenance Use Recorded at       |                 |       |       |       |       |       |       |       |
| 2 Years PostTx                         | 1,752           | 1,604 | 1,706 | 1,703 | 1,661 | 1,645 | 1,624 | 1,534 |
| СуА                                    | 1.6%            | 2.1%  | 1.8%  | 1.2%  | 1.0%  | 1.0%  | 0.7%  | 0.1%  |
| Tac                                    | 1.8%            | 1.8%  | 2.1%  | 2.0%  | 2.0%  | 1.6%  | 2.8%  | 3.1%  |
| + MMF/MPA                              | 0.2%            | 0.1%  | 0.1%  | 0.2%  | 0.2%  | 0.3%  | 0.2%  | 0.1%  |
| CyA + MMF/MPA                          | 13.2%           | 12.3% | 14.1% | 12.9% | 11.4% | 12.0% | 10.8% | 10.8% |
| Tac + MMF/MPA                          | 4.3%            | 5.2%  | 7.2%  | 12.2% | 11.2% | 15.8% | 18.9% | 21.6% |
| + OtherAntimet                         | 0.1%            | 0.1%  | 0.1%  | 0.1%  | 0.0%  | 0.0%  | 0.1%  | 0.0%  |
| CyA + OtherAntimet                     | 7.0%            | 3.9%  | 3.2%  | 2.1%  | 2.0%  | 1.3%  | 1.6%  | 1.1%  |
| Tac + OtherAntimet                     | 1.7%            | 1.7%  | 1.1%  | 1.5%  | 1.6%  | 1.5%  | 1.4%  | 2.1%  |
| + MMF/MPA + OtherAntimet               | 0.0%            | 0.0%  | 0.0%  | 0.1%  | 0.0%  | 0.0%  | 0.1%  | 0.0%  |
| CyA + MMF/MPA + OtherAntimet           | 0.0%            | 0.0%  | 0.0%  | 0.0%  | 0.1%  | 0.0%  | 0.0%  | 0.0%  |
| Tac + MMF/MPA + OtherAntimet           | 0.0%            | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.1%  |
| + Siro/Evero                           | 0.0%            | 0.1%  | 0.0%  | 0.1%  | 0.0%  | 0.1%  | 0.0%  | 0.0%  |
| CyA + Siro/Evero                       | 0.0%            | 0.2%  | 0.6%  | 0.4%  | 1.7%  | 1.5%  | 0.9%  | 0.5%  |
| Tac + Siro/Evero                       | 0.1%            | 0.2%  | 0.4%  | 1.2%  | 2.7%  | 2.5%  | 2.2%  | 2.5%  |
| + MMF/MPA + Siro/Evero                 | 0.0%            | 0.0%  | 0.1%  | 0.2%  | 0.3%  | 0.4%  | 0.7%  | 1.6%  |
| CyA + MMF/MPA + Siro/Evero             | 0.1%            | 0.1%  | 0.1%  | 0.4%  | 0.4%  | 0.4%  | 0.3%  | 0.3%  |
| Tac + MMF/MPA + Siro/Evero             | 0.0%            | 0.0%  | 0.2%  | 0.1%  | 0.3%  | 0.4%  | 0.7%  | 0.5%  |
| + OtherAntimet + Siro/Evero            | 0.0%            | 0.0%  | 0.1%  | 0.1%  | 0.1%  | 0.1%  | 0.2%  | 0.1%  |
| CyA + OtherAntimet + Siro/Evero        | 0.0%            | 0.1%  | 0.1%  | 0.1%  | 0.1%  | 0.0%  | 0.0%  | 0.0%  |
| Tac + OtherAntimet + Siro/Evero        | 0.0%            | 0.0%  | 0.0%  | 0.0%  | 0.2%  | 0.0%  | 0.0%  | 0.0%  |
| + Steroids                             | 1.3%            | 0.5%  | 0.1%  | 0.4%  | 0.3%  | 0.2%  | 0.2%  | 0.3%  |
| CyA + Steroids                         | 3.4%            | 5.4%  | 2.1%  | 1.7%  | 1.4%  | 1.3%  | 0.8%  | 1.0%  |
| Tac + Steroids                         | 2.4%            | 2.8%  | 2.8%  | 3.4%  | 3.0%  | 3.4%  | 3.3%  | 3.3%  |
| + MMF/MPA + Steroids                   | 0.3%            | 0.2%  | 0.2%  | 0.9%  | 0.5%  | 0.2%  | 0.2%  | 0.3%  |
| CyA + MMF/MPA + Steroids               | 32.0%           | 29.9% | 30.9% | 26.0% | 20.8% | 18.9% | 15.8% | 15.1% |
| Tac + MMF/MPA + Steroids               | 13.7%           | 14.5% | 17.6% | 19.9% | 20.5% | 21.4% | 23.6% | 24.4% |
| + OtherAntimet + Steroids              | 0.1%            | 0.1%  | 0.1%  | 0.0%  | 0.1%  | 0.1%  | 0.0%  | 0.0%  |
| CyA + OtherAntimet + Steroids          | 11.6%           | 9.0%  | 5.7%  | 3.0%  | 2.9%  | 1.3%  | 1.7%  | 0.6%  |
| Tac + OtherAntimet + Steroids          | 3.2%            | 2.8%  | 2.8%  | 1.8%  | 2.0%  | 2.0%  | 1.6%  | 1.4%  |
| + Siro/Evero + Steroids                | 0.1%            | 0.2%  | 0.3%  | 0.5%  | 0.6%  | 0.7%  | 0.3%  | 0.4%  |
| CyA + Siro/Evero + Steroids            | 0.2%            | 1.1%  | 1.3%  | 0.8%  | 1.3%  | 2.1%  | 1.2%  | 1.0%  |
| Tac + Siro/Evero + Steroids            | 0.3%            | 1.0%  | 2.1%  | 3.4%  | 4.5%  | 4.1%  | 2.2%  | 2.5%  |
| Other Regimen                          | 1.5%            | 4.7%  | 3.1%  | 3.4%  | 6.7%  | 5.6%  | 7.5%  | 5.3%  |

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Percentages are calculated based on the total number of patients with maintenance use at two years following transplantation. They sum to 100 percent for each column. Transplants prior to year 1998 are not reported due to insufficient reporting of immunosuppressive drug use.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.